Exelixis | EXEL - Assets


Exelixis reported $2.59B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.74B 137.67M Jun/2026
Agios Pharmaceuticals USD 1.11B 76.57M Jun/2026
Akebia Therapeutics USD 349.66M 12.86M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Bayer EUR 107.94B 3.4B Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Cytokinetics USD 1.27B 151.06M Mar/2026
Eisai JPY 1.56T 108.98B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Exelixis USD 2.59B 250.83M Mar/2026
Genmab DKK 12.87B 5.85B Dec/2025
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
Incyte USD 7.87B 533.53M Jun/2026
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Merck USD 128.68B 8.18B Mar/2026
Moderna USD 10.96B 527M Jun/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.36B 452.9M Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Takeda JPY 15.66T 210.16B Jun/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Xencor USD 724.96M 11.89M Jun/2026